104 related articles for article (PubMed ID: 24337664)
1. Upregulation of NEK2 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Oncol Rep; 2014 Feb; 31(2):745-54. PubMed ID: 24337664
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of NEK11 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2014 Sep; 45(3):1266-74. PubMed ID: 24969318
[TBL] [Abstract][Full Text] [Related]
3. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
4. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
[TBL] [Abstract][Full Text] [Related]
5. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
Li J; Zhang Y; Gao Y; Cui Y; Liu H; Li M; Tian Y
Oncol Rep; 2014 Sep; 32(3):979-88. PubMed ID: 24968817
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
Yin F; Liu L; Liu X; Li G; Zheng L; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2014 Jul; 32(1):362-72. PubMed ID: 24842157
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.
Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Int J Oncol; 2013 Apr; 42(4):1305-16. PubMed ID: 23404140
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
[TBL] [Abstract][Full Text] [Related]
11. The in vivo expression pattern of mouse Nek2, a NIMA-related kinase, indicates a role in both mitosis and meiosis.
Tanaka K; Parvinen M; Nigg EA
Exp Cell Res; 1997 Dec; 237(2):264-74. PubMed ID: 9434622
[TBL] [Abstract][Full Text] [Related]
12. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
13. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans.
Schultz SJ; Fry AM; Sütterlin C; Ried T; Nigg EA
Cell Growth Differ; 1994 Jun; 5(6):625-35. PubMed ID: 7522034
[TBL] [Abstract][Full Text] [Related]
15. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
17. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Zhou W; Yang Y; Xia J; Wang H; Salama ME; Xiong W; Xu H; Shetty S; Chen T; Zeng Z; Shi L; Zangari M; Miles R; Bearss D; Tricot G; Zhan F
Cancer Cell; 2013 Jan; 23(1):48-62. PubMed ID: 23328480
[TBL] [Abstract][Full Text] [Related]
18. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM
Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258
[TBL] [Abstract][Full Text] [Related]
19. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.
Kokuryo T; Yokoyama Y; Yamaguchi J; Tsunoda N; Ebata T; Nagino M
Anticancer Res; 2019 May; 39(5):2251-2258. PubMed ID: 31092416
[TBL] [Abstract][Full Text] [Related]
20. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
